Article Text

Download PDFPDF

P058 S100 proteins effectively discriminate systemic lupus erythematosus patients from healthy controls, but are not associated with measures of disease activity
  1. B Šumová1,2,
  2. J Závada1,2,
  3. LA Cerezo2,
  4. M Uher3,
  5. H Hulejová2,
  6. M Grigorian4,
  7. K Pavelka1,2,
  8. J Vencovský1,2,
  9. L Šenolt1,2
  1. 1Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
  2. 2Institute of Rheumatology, Prague, Czech Republic, Prague
  3. 3Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
  4. 4Department of Neuroscience, University of Copenhagen, Copenhagen, Denmark


Introduction The S100 proteins are important regulators of diverse calcium-dependent cellular processes including growth regulation, migration and apoptosis. Dysregulated expression of multiple members of S100 family is a common feature of cancer and several autoimmune diseases.

Objectives The aim of this study was to examine whether circulating levels of S100A4, S100A8/9 and S100A12 proteins could be useful as diagnostic or activity specific markers in systemic lupus erythematosus (SLE).

Methods S100 plasma levels were measured by ELISA in a cohort study of 44 patients with SLE, 8 patients with incomplete SLE (iSLE) and 43 healthy controls (HCs). Disease activity was assessed using SLEDAI-2 K. We examined cross sectional associations between concentrations of S100 proteins and SLE status, SLEDAI-2 K scores, and levels of conventional biomarkers.

Results Plasma levels of all analysed S100 proteins (S100A4, S100A8/9 and S100A12) were significantly higher in SLE patients compared to HCs (p<0.001, p<0.01, p<0.001, respectively). In iSLE patients, the levels of S100A4 and S100A12 but not S100A8/9 were significantly higher compared to HCs (p<0.001, p<0.05, p=ns, respectively). ROC curve analysis was performed to establish the optimal threshold to discriminate SLE patients from HCs based on S100 levels. At the optimal cutoff point of 238 ng/ml, the area under curve (AUC) for S100A4 was 0–990 (95% CI: 0.977 to 1.000, p<0.001) with a sensitivity of 96% and specify of 93.0%. The remaining two proteins also showed significant, but not as strong discriminative value [S100A8/9: AUC 0.684 (95% CI: 0.572 to 0.795, p<0.05); S100A12: AUC 0.809 (95% CI: 0.719 to 0.898, p<0.001]. We found that only S100A12 levels were significantly associated with the SLEDAI-2K score (r=0.318, p=0.035). Both S100A8/9 and S100A12 levels were significantly higher in SLE patients with arthritis (p=0.043, p=0.015, respectively) and with haematological features (p=0.002 for both). There were no other significant associations between S100 levels and other conventional markers such as C3, C4 and the anti-dsDNA antibodies.

Conclusions We demonstrate increased S100 proteins expression in SLE patients. Although they were not strongly associated with disease activity, S100 proteins and namely S100A4 could be proposed as a diagnostic biomarker for SLE.

Acknowledgements MHCR for conceptual development of research organisation 00023728 and SVV 260 373.

Disclosure of interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.